Is etanercept safe for treating plaque psoriasis in a patient with chronic hepatitis C virus infection?

Archives of Dermatology

Volumn 146, Issue 10, 2010, Pages 1151-1152

  Gandhi, Rishi K ^a   Pickup, Tiffany ^b   Sheth, Pranav B ^c  

^a WRIGHT STATE UNIVERSITY   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c Group Health Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; ETANERCEPT; RIBAVIRIN; VIRUS RNA; IMMUNOGLOBULIN G; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ARTICLE; CASE REPORT; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MALE; NONHUMAN; PRIORITY JOURNAL; PSORIASIS VULGARIS; TREATMENT OUTCOME; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; COMPLICATION; MIDDLE AGED; PSORIASIS;

HEPATITIS C, CHRONIC; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77958161310     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2010.253     Document Type: Article

References (14)

1. National Digestive Diseases Information Clearinghouse. Chronic hepatitis C: current disease management [cited October 12, 2009]. http://digestive.niddk. nih .gov/ddiseases/pubs/chronichepc/. Accessed September 12, 2009.
2. McClure SL, Valentine J, Gordon KB. Comparative tolerability of systemic treatments for plaque-type psoriasis. Drug Saf. 2002;25(13):913-927. (Pubitemid 35252717)
3. Lebwohl M. Combining the new biologic agents with our current psoriasis armamentarium. J Am Acad Dermatol. 2003;49(2)(suppl):S118-S124. (Pubitemid 36951256)
4. Prignano F, Zanieri F, Milani S, Lotti T. Switch from etanercept to efalizumab in a psoriatic patient with HCV infection: a case report. Dermatol Ther. 2009;22 (4):386-390.
5. Gisondi P, Prignano F, Grossi P, Lotti T, Girolomoni G. Treatment of psoriasis with efalizumab in patients with hepatitis C viral infection: report of five cases. Dermatology. 2009;219(2):158-161.
6. Nelson DR, Lim HL, Marousis CG, et al. Activation of tumor necrosis factor-α system in chronic hepatitis C virus infection. Dig Dis Sci. 1997;42(12):2487-2494.
7. Zein NN; Etanercept Study Group. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol. 2005; 42(3):315-322.
8. De Simone C, Paradisi A, Capizzi R, Carbone A, Siciliano M, Amerio PL. Etanercept therapy in two patients with psoriasis and concomitant hepatitis C. J Am Acad Dermatol. 2006;54(6):1102-1104.
9. Magliocco MA, Gottlieb AB. Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: report of 3 cases. J Am Acad Dermatol. 2004;51(4):580-584.
10. Cecchi R, Bartoli L. Psoriasis and hepatitis C treated with anti-TNF alpha therapy (etanercept). Dermatol Online J. 2006;12(7):4.
11. Rokhsar C, Rabhan N, Cohen SR. Etanercept monotherapy for a patient with psoriasis, psoriatic arthritis, and concomitant hepatitis C infection. J Am Acad Dermatol. 2006;54(2):361-362. (Pubitemid 43144420)
12. Collazo MH, González JR, Torres EA. Etanercept therapy for psoriasis in a patient with concomitant hepatitis C and liver transplant. P R Health Sci J. 2008; 27(4):346-347.
13. Behnam SE, Hindiyeh R, Fife DJ, Jeffes EW III, Wu JJ. Etanercept as prophylactic psoriatic therapy before interferon-α and ribavirin treatment for active hepatitis C infection. Clin Exp Dermatol. 2010;35(4):397-398.
14. Frankel AJ, Van Voorhees AS, Hsu S, et al; National Psoriasis Foundation. Treatment of psoriasis in patients with hepatitis C: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2009;61(6):1044-1055.